PrEP Trial Results
iPrEx -
Phase III safety and effectiveness trial of
once-daily TDF/FTC (Truvada) in gay men,
transgender women and other men who have sex
with men
CDC 4323 - Phase II extended safety trial of once-daily TDF in gay men and other MSM in the US
FHI TDF West African Trial - Phase II trial of once-daily TDF in women in Cameroon, Ghana and Nigeria
- Visit AVAC's dedicated iPrEx trial page for the latest
- Visit the iPrEx trial team page
CDC 4323 - Phase II extended safety trial of once-daily TDF in gay men and other MSM in the US
- CDC release: Preliminary Results from First Safety Study of Daily Tenofovir for HIV Prevention Among MSM Find No Significant Concerns
- Preliminary
Safety and Adherence Data from Oral PrEP Trial
Released; Trial Not Designed to Evaluate
Effectiveness - AVAC statement on
the results
- Read the Advocates' Network update covering these results and other ARV-based prevention data reported at AIDS 2010
- Trial design fact sheet
FHI TDF West African Trial - Phase II trial of once-daily TDF in women in Cameroon, Ghana and Nigeria
- Findings
from trial of tenofovir disoproxil fumarate
(TDF) for prevention of HIV infection in
women - Published in PLoS Clinical Trials,
May 25, 2007
- Findings from a double-blind, randomized, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) for prevention of HIV infection in women: AIDS 2006 abstract; AIDS 2006 PowerPoint presentation